Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2023-08-14 Regulatory Filings
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2023-08-14 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis for the Three and Six Months Ended June 30, 2023' and contains detailed financial discussion, including non-IFRS measures, financial results, and operational overview for the specified interim period. It references unaudited condensed interim consolidated financial statements and discusses financial performance and business trends for the quarter and half-year periods. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive interim report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2023
2023-08-10 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO of HLS Therapeutics Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2023. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, including controls over financial reporting. It does not contain the actual interim financial statements or substantive financial data itself, but rather attests to their validity. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is 3351 characters, which is relatively short and consistent with a certification letter rather than a full report. Therefore, the correct classification is Regulatory Filings (RNS).
2023-08-10 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2023. It is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing substantive financial data or the actual interim report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS), not as the interim report (IR) they reference.
2023-08-10 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements' for HLS Therapeutics Inc. for the three and six months ended June 30, 2023. It contains detailed financial statements including the statement of financial position, statement of loss, statement of comprehensive loss, statement of changes in shareholders' equity, and statement of cash flows. The notes indicate compliance with International Accounting Standard 34 for interim financial reporting. The document is unaudited and covers a period shorter than a full fiscal year (quarterly and half-year data). This matches the definition of an Interim / Quarterly Report (IR). The document is substantive and contains actual financial data and analysis, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. H1 2023
2023-08-10 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of HLS Therapeutics' Q2 Fiscal 2023 financial results, including revenue, operating expenses, net loss, and adjusted EBITDA. It contains comprehensive financial data for the three- and six-month periods ended June 30, 2023, and discusses operational highlights, financial review, and forward-looking statements. The presence of detailed financial tables and management commentary indicates this is a full interim financial report rather than a brief earnings release or a simple announcement. The document also references the availability of the Management's Discussion and Analysis and Consolidated Financial Statements on the company's website and SEDAR+, which supports that this document itself is the financial results announcement. The inclusion of a conference call announcement and webcast link is typical for quarterly earnings releases. Given the detailed financial data and analysis for a period shorter than a full fiscal year, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2023
2023-08-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.